Progesterone receptor status is a significant prognostic variable of progression-free survival in advanced epithelial ovarian cancer

American Journal of Clinical Oncology: Cancer Clinical Trials

Volumn 21, Issue 5, 1998, Pages 447-451

  Hempling, Ronald E ^a   Piver, M Steven ^a   Eltabbakh, Gamal H ^a   Recio, Fernando O ^a  

^a ROSWELL PARK CANCER INSTITUTE   (United States)

Author keywords

Estrogen receptor; Ovarian cancer; Progesterone receptor; Survival

Indexed keywords

CISPLATIN; CYCLOPHOSPHAMIDE; DOXORUBICIN; ESTROGEN RECEPTOR; PROGESTERONE RECEPTOR;

ADULT; ADVANCED CANCER; AGED; ARTICLE; CANCER STAGING; CANCER SURVIVAL; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; MAJOR CLINICAL STUDY; OVARY CANCER; RECEPTOR BINDING; RECEPTOR DENSITY;

ADULT; AGED; FEMALE; HUMANS; MIDDLE AGED; MULTIVARIATE ANALYSIS; NEOPLASM STAGING; NEOPLASMS, HORMONE-DEPENDENT; OVARIAN NEOPLASMS; PROGNOSIS; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE; SURVIVAL ANALYSIS;

EID: 0031754623     PISSN: 02773732     EISSN: None     Source Type: Journal    
DOI: 10.1097/00000421-199810000-00005     Document Type: Article

References (23)

1. McGuire WL. Steroid receptors in human breast cancer. Cancer Res 1978;38:4289-91.
2. Bloom ND, Tobin EH, Schreiberman B, et al. The role of progesterone receptors in the treatment of breast cancer. Cancer Res 1980;45:2992-7.
3. Osborne CK, Yochmowitz MG, Knight WA, et al. The value of estrogen and progesterone receptors in the treatment of breast cancer. Cancer 1980;46:2884-8.
4. Benraad THJ, Friberg CG, Koenders AJM, et al. Do estrogen and progesterone receptors (ER and PR) in metastasizing endometrial cancer predict response to estrogen therapy. Acta Obstet Gynecol Scand 1980;59:155-9.
5. Ehrlich CE, Young PLM, Cleary RE. Cytoplasmic progesterone and estradiol receptors in normal, hyperplastic and carcinomatous endometria. therapeutic implications. Am J Obstet Gynecol 1981;141:539-46.
6. Kaupilla A. Progestin therapy of endometrial breast and ovarian carcinoma. a review of clinical observations. Acta Obstet Gynecol Scand 1984;63:441-50.
7. Schwartz PE, MacLusky N, Merino MJ, et al. Are cytosol estrogen and progestin receptors of prognostic significance in the management of epithelial ovarian cancer. Obstet Gynecol 1986;68:751-8.
8. Bizzi A, Codegoni AM, Landoni F, et al. Steroid receptors in epithelial ovarian cancer. relation to clinical parameters and survival. Cancer Res 1988;48:6222-6.
9. Slotman BJ, Kuhnel R, Ramanath B, et al. Importance of steroid receptors and aromatase activity in the prognosis of ovarian cancer. high tumor progesterone receptor levels correlate with longer survival. Gynecol Oncol 1989;33:76-81.
10. Rose PG, Reace FR, Longcope C, Huter RE. Prognostic significance of estrogen and progesterone receptors in epithelial ovarian cancer. Obstet Gynecol 1990;76:258-63.
11. Sevelda P, Denison U, Schemper M, et al. Oestrogen and progesterone receptor content as a prognostic factor in advanced epithelial ovarian carcinoma. Br J Obstet Gynecol 1990;97:706-12.
12. Kommoss F, Pfisterer J, Thome M, et al. Steroid receptors in ovarian carcinoma. immunohistochemical determination may lead to new aspects. Gynecol Oncol 1992;47:317-22.
13. Geisler JP, Wiemann MC, Miller GA, Geisler HE. Estrogen and progesterone receptor status as prognostic indicators in patients with optimally cytoreduced stage IIIC serous cystadenocarcinoma of the ovary. Gynecol Oncol 1986;60:424-7.
14. Anderl P, Fuith L, Daxenbichler G, et al. Correlation between steroid receptors, histologic and clinical parameters in ovarian carcinoma. Obstet Gynecol Invest 1988;25:135-40.
15. Masood S, Heitmann J, Nuss RC, Benrubi GI. Clinical correlation of hormone receptor status in epithelial ovarian cancer. Gynecol Oncol 1989;34:57-60.
16. DeHertagh R, VanderHeyden I, Edda EJ. "Unbound" ligand absorption on dextran-coated charcoal: practical consideration. J Steroid Biochem 1975;6:1333-7.
17. Friedlander M, Quinn MA, Fontune D, et al. The relationship of steroid receptor expression to nuclear DNA distribution and clinicopathologic characteristics in epithelial ovarian tumors. Gynecol Oncol 1989;32:184-90.
18. Erhardt K, Aver G, Bjorkholm E, et al. Prognostic significance of DNA content in serous ovarian tumors. Cancer Res 1984;44:2198-202.
19. Volm M, Bruggeman A, Gunther M, et al. Prognostic significance of ploidy and proliferation in ovarian carcinoma. Cancer Res 1985;45:5180-5.
20. Rodendurg CJ, Cornelisse CJ, Heintz PA, et al. Tumor ploidy as a major prognostic factor in advanced ovarian cancer. Cancer 1987;59:317-23.
21. Schwartz RE, Keating G, Maclusky N, et al. Tamoxifen therapy for advanced ovarian cancer. Obstet Gynecol 1982;59:583-8.
22. Schwartz PE, Chambers JT, Kohorn EI, et al. Tamoxifen in combination with cytotoxic chemotherapy in advanced epithelial ovarian cancer: a prospective randomized trial. Cancer 1989;63:1074-8.
23. Hatch KD, Beecham JB, Blessing JA, Creasman WT. Responsiveness of patients with advanced ovarian carcinoma to tamoxifen. a Gynecologic Oncology Group study of second-line therapy in 105 patients. Cancer 1991;68:269-71.